13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
45 檔
30.8%
At the close of Q4 2025, Catalio Capital Management, LP disclosed equity holdings valued at approximately $532.1M, spread across 45 reported holdings.
During Q4 2025, Catalio Capital Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | Stock-Healthcare | 6.28% | +1.62% | — | |
| 2 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 6.18% | -0.86% | — | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 6.07% | -3.92% | EXIT | |
| 4 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 5.55% | +0.46% | NEW | |
| 5 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.92% | — | -54.82% | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.76% | -9.22% | -2.10% | |
| 7 | ASND | Ascendis Pharma A/S | Stock-Other | 4.49% | -6.17% | EXIT | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.44% | -0.10% | -25.88% | |
| 9 | JNJ | Johnson & Johnson | Stock-Healthcare | 4.42% | +6.63% | NEW | |
| 10 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 4.07% | — | -15.69% | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.11% | +0.22% | -61.20% | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.95% | -4.04% | EXIT | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.90% | -2.97% | EXIT | |
| 14 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.82% | -0.30% | — | |
| 15 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.72% | — | -61.86% | |
| 16 | NTRA | Natera Inc | Stock-Healthcare | 2.52% | +1.23% | -58.03% | |
| 17 | ADPT | Adaptive Biotechnologies | Stock-Other | 2.36% | -2.10% | EXIT | |
| 18 | ABVX | Abivax Sa-adr | Stock-Other | 2.35% | -1.10% | EXIT | |
| 19 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 2.26% | -0.67% | EXIT | |
| 20 | GUTS | Fractyl Health Inc | Stock-Other | 2.14% | +0.39% | +5.32% | |
| 21 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.13% | +0.81% | — | |
| 22 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 2.05% | -0.57% | EXIT | |
| 23 | ADMA | Adma Biologics Inc | Stock-Healthcare | 1.82% | — | -17.54% | |
| 24 | ACLXGBX | Arcellx Inc | Stock-Other | 1.80% | — | — | |
| 25 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.80% | -0.05% | — | |
| 26 | IRON | Disc Medicine Inc | Stock-Other | 1.55% | +0.55% | -49.00% | |
| 27 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.53% | — | — | |
| 28 | SEPN | Septerna Inc | Stock-Other | 1.45% | +1.89% | — | |
| 29 | TARA | Protara Therapeutic Inc | Stock-Other | 1.36% | -0.26% | -3.63% | |
| 30 | QURE | uniQure N.V. | Stock-Other | 1.22% | -1.68% | EXIT | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.18% | — | — | |
| 32 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.98% | -4.50% | EXIT | |
| 33 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.66% | -1.74% | -44.19% | |
| 34 | HTFL | Heartflow Inc | Stock-Other | 0.59% | +1.17% | — | |
| 35 | GRAL | Grail Inc | Stock-Healthcare | 0.46% | — | -78.02% | |
| 36 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 37 | BLLN | Billiontoone Inc Cl A | Stock-Other | 0.37% | — | — | |
| 38 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.34% | +0.20% | +18.72% | |
| 39 | HYPR | Hyperfine Inc | Stock-Other | 0.23% | +0.03% | +92.84% | |
| 40 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.19% | — | -12.97% | |
| 41 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.19% | +0.69% | — | |
| 42 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.15% | -0.03% | — | |
| 43 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.14% | — | — | |
| 44 | OM | Outset Medical Inc | Stock-Other | 0.08% | +0.01% | — | |
| 45 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.03% | -0.03% | — |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 45 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GILD, BMY, BSX) accounted for 30.8% of total reported equity market value during Q4 2025.
During Q4 2025, Catalio Capital Management, LP's top holdings by market value included GILD (6.3%)、BMY (6.2%)、BSX (6.1%). The largest single position, GILD, represented 6.3% of total portfolio value.
In Q4 2025, Catalio Capital Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.